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Females
Objective. Adolescent females' HPV vaccine completion in the U.S. is low. More recent research is needed to
investigate factors that relate to HPV vaccine completion among female adolescents in the United States.
Methods. Provider-validated data from the 2012 National Immunization Survey-Teen for females ages
13–17 years (N = 9058) were analyzed from February–May 2014 using survey sample weighted statistics.
Amultivariable Poisson regression estimated prevalence ratios (PR) for factors inﬂuencingHPVvaccine completion:
mother's education, poverty status, adolescent's grade, facility type, and receipt of other adolescent vaccinations.Results. In multivariable models, 9–12th grade daughters weremore likely to complete HPV vaccination than
6–8th grade daughters (PR = 1.81, 95% CI = 1.58–2.06). Those seen in hospital facilities completed HPV vacci-
nation 1.3 times more (PR = 1.29, 95% CI = 1.02–1.62) and those seen in private facilities were 1.2 times
more likely to complete (PR = 1.22, 95% CI = 1.01–1.48), than those seen in public facilities, respectively.
Compared to those without recommended adolescent vaccinations, receipt of seasonal inﬂuenza vaccination re-
lated to HPV vaccine completion (PR=1.71, 95% CI=1.54–1.89), as did receipt of TDAP vaccination (PR=1.17,
95% CI = 1.03–1.33) and Meningitis vaccination (PR = 2.74, 95% CI = 2.20–3.42).
Conclusions. Adolescent females in high school, seen in private/hospital facilities, and up to date on other
recommended adolescent vaccinations are most likely to complete the HPV vaccine.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Background
TheHealthy People 2020HPV vaccination goal among females is 80%
(Healthy People, 2020 Topics & Objectives: U.S. Department of Health
and Human Services, 2014). In 2012, 33.4% of eligible adolescents
have completed HPV vaccination in the United States (U.S.), with varia-
tion among states (Mississippi= 12.1% to Rhode Island=57.7%) (2012
NIS-Teen Vaccination Coverage Table Data: Centers for Disease Control
and Prevention, 2014).
In 2010, minority race adolescents were more likely to initiate the
HPV vaccine, (Laz et al., 2012) but less likely to complete the series
(Niccolai et al., 2011; Reiter et al., 2014). In 2009, older adolescents5, Salt Lake City, UT 84112, USA.
ka), Qian.Ding@utah.edu
ael.Spigarelli@hsc.utah.edu
ey).
. This is an open access article underwere less likely to complete HPV vaccination than younger patients
(Hirth et al., 2012). Those living below poverty level are less likely to
complete HPV vaccination (Niccolai et al., 2011). Research is needed
to provide updated data on factors inﬂuencing HPV vaccine completion.
This is one of the ﬁrst studies of 2012 National Immunization
Survey-Teen (NIS-Teen) data to investigate HPV vaccine completion
factors among female adolescents in the U.S. Those individuals whose
mother had lower education, living below poverty level, of racial or eth-
nic minority, younger adolescents, and receiving the vaccine at private
facilities, or from a Vaccine for Children provider were hypothesized
to have lower completion of the HPV vaccine. Individuals with other
adolescent vaccinations were expected to be more likely to complete
the HPV vaccine than those without other vaccines.
Methods
This secondary data analysis occurred from February–May 2014 and
utilized the 2012 NIS-Teen survey, a publicly available, nationallythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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where (Jain et al., 2009). Annually, the NIS-Teen uses random digit
dialing to sample parents and adolescent health care providers through
a telephone and mailed survey, respectively. These data assess adoles-
cent vaccination coverage among 13–17 year olds in the U.S. The 2012
NIS-Teen had a cellular-household response rate of 23.6%, and a
landline-household response rate of 55.1% (National State Vaccination
Coverage Among Adolescents Aged 13–17 Years — United States,
2012, 2014). Analysis of publicly available data is considered exempt
research by the University of Utah Institutional Review Board.Table 1
Bivariate analysis of female respondent characteristics: full sample and those with HPV compl
Tota
(N =
Age (mother)
≤34 years 671
35–44 years 3709
≥45 years 4678
Education (mother)
b12 years 905
12 years 1723
N12 years (some college) 2547
College graduate 3883
Poverty status
Above poverty (N$75 k) 3943
Above poverty (≤$75 k) 3335
Below poverty 1515
Missing, n (%) 265
Marital status (mother)
Married 6691
Other 2367
Adolescent's race/ethnicity
Hispanic 1231
Non-Hispanic White only 6058
Non-Hispanic Black only 899
Other 870
Adolescent's current grade
6th to 8th grade 2511
9th to 12th grade 6441
HS graduate/GED 106
Adolescent's health insurance
Employment/union 5928
Other 3054
Missing, n (%) 76 (0
Facility type for adolescent's providers
All public facilities 1270
All hospital facilities 793
All private facilities 4213
Mixed/other 2427
Missing, n (%) 355
Do adolescent's providers order vaccinations from state/local health department
All providers 5988
Some but possibly not all 1309
No providers 1008
Don't know 728
Missing, n (%) 25 (0
Inﬂuenza vaccinationf
Yes 3850
No 5208
TDAP vaccinationg
Yes 6085
No 2973
Meningitis vaccinationh
Yes 6657
No 2401
a Respondents from the Virgin Islands were excluded.
b Female adolescents in the U.S. with adequately complete provider-reported immunization
c Weighted percentages from Dual-Frame Sampling Weights.
d HPV completion includes those who had received at least 3 doses of the HPV vaccine.
e Survey weighted Pearson chi-square test compared those with HPV vaccine completion to
f Adolescent has taken at least one dose of seasonal inﬂuenza vaccination in the past three y
g Adolescent has taken at least one dose of TDAP only vaccination since age 10 years old an
h Adolescent has taken at least one dose of Meningitis vaccination.The Andersen healthcare utilization model guided the selection
of factors examined in this study. Health services use is determined
by three components: predisposing factors, enabling factors, and
need. Predisposing factors include patient and caregiver/parent de-
mographics (e.g., age, education, marital status, race, and income).
Enabling factors include access to insurance, provider access to vac-
cinations, and access to other adolescent immunizations. Need in-
cludes perceived need for healthcare services which may relate to
parent prioritization of other recommended adolescent vaccinations
(Anderson, 1995).etiona,b. Bold indicates statistically signiﬁcant p-values that are less than p=0.05.
l
9058)
%c (95% CI) HPV completiond
(N = 3246)
%c (95% CI) p-Valuee
0.738
10.0 (8.8, 11.4) 217 10.4 (8.1, 13.2)
45.3 (43.5, 47.2) 1304 44.2 (41.1, 47.4)
44.6 (42.8, 46.5) 1725 45.4 (42.3, 48.5)
0.007
14.3 (12.8, 15.9) 352 16.7 (14.0, 19.7)
24.0 (22.4, 25.8) 615 23.7 (21.1, 26.5)
27.8 (26.1, 29.5) 836 24.1 (21.6, 26.8)
33.9 (32.3, 35.6) 1443 35.5 (32.7, 38.5)
0.048
33.4 (31.8, 35.1) 1472 34.4 (31.6, 37.3)
39.2 (37.3, 41.0) 1101 35.9 (32.9, 39.1)
27.4 (25.6, 29.4) 587 29.7 (26.5, 33.0)
(2.93) 86 (2.65)
0.944
64.0 (62.1, 65.9) 2354 64.1 (60.9, 67.1)
36.0 (34.1, 37.9) 892 35.9 (32.9, 39.1)
0.262
21.8 (20.1, 23.7) 455 23.2 (20.2, 26.5)
54.2 (52.4, 56.1) 2151 54.7 (51.5, 57.8)
14.2 (12.9, 15.7) 306 12.3 (10.4, 14.6)
9.7 (8.6, 11.0) 334 9.8 (8.0, 11.9)
b0.001
27.1 (25.5, 28.7) 590 18.0 (15.8, 20.5)
71.5 (69.8, 73.1) 2615 80.9 (78.5, 83.2)
1.4 (1.0, 2.1) 41 1.0 (0.6, 1.7)
0.475
56.6 (54.7, 58.5) 2102 55.6 (52.4, 58.8)
43.4 (41.5, 45.3) 1118 44.4 (41.2, 47.6)
.84) 26 (0.80)
b0.001
15.5 (14.1, 17.0) 367 12.1 (10.0, 14.5)
7.4 (6.5, 8.3) 337 8.1 (6.6, 9.8)
50.8 (49.0, 52.7) 1567 55.4 (52.2, 58.6)
26.3 (24.7, 28.0) 861 24.5 (21.9, 27.3)
(3.92) 114 (3.51)
0.052
64.5(62.6, 66.3) 2232 67.3 (64.2, 70.2)
14.0 (12.8, 15.4) 466 13.9 (11.8, 16.4)
11.7 (10.6, 12.9) 316 11.0 (9.3, 12.9)
9.8 (8.6, 11.2) 232 7.9 (6.3, 9.7)
.28)
b0.001
38.9 (37.2, 40.7) 1887 56.0 (52.8, 59.1)
61.1 (59.3, 62.8) 1359 44.0 (40.9, 47.2)
b0.001
65.0 (63.2, 66.8) 2465 72.4 (69.2, 75.4)
35.0 (33.2, 36.9) 781 27.6 (24.7, 30.7)
b0.001
73.5 (71.7, 75.1) 2916 90.7 (88.5, 92.4)
26.5 (24.9, 28.3) 330 9.3 (7.6, 11.5)
records in the 2012 NIS-Teen survey were included in the analysis.
those who did not receive 3 doses.
ears.
d before 13 years old.
Table 2
Multivariable analysis of factors predicting HPV vaccine completion among female
adolescents, NIS-Teen 2012a.
Adjusted vaccination
coverageb% (95% CI)
Prevalence ratioc
(95% CI)
Age (mother)
≤34 years 37.8 (30.0, 45.6) Reference
35–44 years 33.4 (30.7, 36.1) 0.88 (0.71, 1.10)
≥45 years 32.9 (30.4, 35.3) 0.87 (0.70, 1.09)
Education (mother)
b12 years 38.0 (32.0, 44.1) Reference
12 years 34.3 (30.4, 38.1) 0.90 (0.75, 1.09)
N12 years (some college) 30.9 (27.7, 34.0) 0.81 (0.67,0.99)
College graduate 33.4 (30.3, 36.6) 0.88 (0.72, 1.07)
Poverty status
Above poverty (N$75 k) 32.9 (29.6, 36.1) Reference
Above poverty (b=$75 k) 32.9 (30.1, 35.7) 1.00 (0.88, 1.13)
Below poverty 35.4 (31.0, 39.9) 1.08 (0.90, 1.29)
Marital status (mother)
Married 32.9 (30.6, 35.2) Reference
Other 34.8 (31.4, 38.2) 1.06 (0.93, 1.20)
Adolescent's race/ethnicity
Hispanic 33.0 (28.4, 37.6) Reference
Non-Hispanic White only 35.8 (33.4, 38.1) 1.08 (0.93, 1.27)
Non-Hispanic Black only 28.1 (23.4, 32.8) 0.85 (0.69, 1.06)
Other 31.8 (26.7, 36.8) 0.96 (0.78, 1.19)
Adolescent's current grade
6th to 8th grade 21.3 (18.7, 24.0) Reference
9th to 12th grade 38.6 (36.3, 40.8) 1.81 (1.58, 2.07)
HS graduate/GED 32.7 (15.6, 49.8) 1.53 (0.90, 2.62)
Adolescent's health insurance
Employment/union 32.8 (30.2, 35.4) Reference
Other 34.6 (31.6, 37.7) 1.06 (0.93, 1.20)
Facility type for adolescent's providers
All public facilities 28.8 (23.9, 33.7) Reference
All hospital facilities 36.8 (31.0, 42.6) 1.28 (1.01, 1.61)
All private facilities 34.7 (32.1, 37.4) 1.21 (1.00, 1.45)
Other 32.9 (29.2, 36.5) 1.14 (0.93, 1.40)
Do adolescent's providers order
vaccinations from state/local
health department
All providers 34.6 (32.5, 36.8) Reference
Some but possibly not all 29.9 (24.9, 34.9) 0.86 (0.72, 1.04)
No providers 35.0 (30.1, 40.0) 1.01 (0.87, 1.18)
Don't know 28.6 (22.5, 34.6) 0.82 (0.66, 1.03)
Inﬂuenza vaccinationd
Yes 44.1 (41.3, 46.9) 1.71 (1.54, 1.90)
No 25.8 (23.6, 28.1) Reference
TDAP vaccinatione
Yes 35.3 (33.1, 37.4) 1.18 (1.04, 1.35)
No 29.8 (26.4, 33.3) Reference
Meningitis vaccinationf
Yes 39.1 (36.9, 41.3) 2.75 (2.20, 3.42)
No 14.2 (11.2, 17.2) Reference
a Respondents from the Virgin Islandswere excluded aswere thosewithmissing values
(N= 8388). Female adolescents in the U.S. with adequately complete provider-reported
immunization records in the 2012 NIS-Teen survey were included in the analysis.
b Multivariable Poisson regression.
c Predictive marginal prevalence.
d Adolescent has taken at least one dose of seasonal inﬂuenza vaccination in the past
three years.
e Adolescent has taken at least one dose of TDAP only vaccination since age 10 years old
and before 13 years old.
f Adolescent has taken at least one dose of Meningitis vaccination.
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Parents consented to have their adolescent's provider contacted
to verify vaccine receipt (About the National Immunization Survey:
Centers for Disease Control and Prevention, 2014). Female adolescents
with provider-veriﬁed immunization records were included in the anal-
ysis (N = 9058).
Outcome measures
The outcome of interest was completion of the 3-dose HPV vac-
cine series. After phone interviews were conducted with parents or
guardians, providers were mailed a questionnaire to acquire provider-
conﬁrmed immunization information for receipt of 3 doses of the vaccine
(Centers for Disease Control and Prevention. National, Regional, State,
and Selected Local Area Vaccination Coverage Among Adolescents Aged
13–17 Years — United States, 2013). Participants with provider veriﬁed
receipt of three doses were considered to have completed the vaccine.
Variable weights selected adjust for respondents with missing provider
data.
Statistical analysis
Provider-phase sampling weight for both landline and cell-phone
samples in the U.S. proper was used to produce Dual-Frame point esti-
mates and 95% conﬁdence intervals (CI). Missing values of each variable
were excluded. Frequency counts, percents, and 95% CI, each properly
weighted by survey sampling weights, were reported for the total sam-
ple and HPV vaccine completion subgroup. For categorical variables, a
surveyweighted Pearson chi-square test was used to compare distribu-
tions between those with HPV vaccine completion to those with less
than 3 doses. A survey weighted multivariable Poisson regression was
ﬁtted to assess the impact of selected predictors and reported as an
adjusted prevalence ratio (PR) with 95% CI. All tests were two-sided
comparisons in STATA version 13.1 (College Station, Texas).
Results
Therewere 9058 respondentswith provider-veriﬁed vaccination re-
cords and daughters ages 13–17 years. Of these, 3246 had completed
the HPV vaccine series. In Table 1, mothers were mostly aged ≥35, col-
lege graduates, and married. Adolescents were primarily living above
poverty level, Non-Hispanic White, 9th–12th grade, and on private
health insurance. In bivariate analyses of female adolescent characteris-
tics, comparing those who had completed the HPV vaccine to those
who had not, demographic factors related to HPV vaccine completion
included: mother's education, poverty status, and adolescent's current
grade, all p b 0.05. Healthcare factors associated with HPV vaccine com-
pletion included facility type for adolescent's providers and completion
of other recommended adolescent vaccinations (i.e., inﬂuenza, TDAP,
Meningitis), all p b 0.05.
Multivariable analysis of factors predicting HPV vaccine completion among
female adolescents
In Table 2, respondentswhosemothers had some college, but no col-
lege degree, were less likely to complete the HPV vaccine than those
whose mothers had less than 12 years of education (PR = 0.81, 95%
CI = 0.67–0.99, p = 0.036). Daughters in 9–12th grade were 1.8 times
more likely to have completed HPV vaccination than those in 6–8th
grade (PR = 1.81, 95% CI = 1.58–2.07, p b 0.001). Female adolescents
who were seen in hospital facilities were 1.3 times more likely to com-
plete (PR= 1.28, 95% CI= 1.01–1.61, p= 0.037) and those seen in pri-
vate facilities were 1.2 times more likely to complete (PR = 1.21, 95%
CI = 1.00–1.45, p = 0.050), compared to those seen in public facilities.Similar to the bivariate analyses, receipt of other adolescent vaccina-
tions increased the likelihood of HPV vaccine completion. Those with at
least one dose of seasonal inﬂuenza vaccination in the past three years
were 1.7 times more likely to complete HPV vaccination (PR = 1.71,
95% CI = 1.54–1.90, p b 0.001) than those without inﬂuenza vaccina-
tion. Adolescents with at least one dose of TDAP vaccination ages
10–13 years were 1.2 times more likely to complete HPV vaccination
(PR= 1.18, 95% CI = 1.04–1.35, p= 0.012) than thosewho had not re-
ceived TDAP. Adolescents with at least oneMeningitis vaccination were
2.7 timesmore likely to complete HPV vaccination than those without a
Meningitis vaccination (PR = 2.75, 95% CI = 2.20–3.42, p b 0.001).
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factors related to females who received three doses of the HPV
vaccine among thosewho had aminimum of 24 weeks between the re-
ceipt of the ﬁrst dose of the HPV vaccine and the date of the inter-
view (n = 4548). Females in higher grades were more likely to
complete the 3-dose HPV vaccine series than females in 6th–8th
grades (p b .001). Females attending private facilities compared to
public facilities (p b .01), and females with the ﬂu and TDAP vac-
cines (both p b .05) were also more likely to complete the 3-dose
series within the recommended time frame (data not shown).
Discussion
Prevalence of HPV types 6, 11, 16 and 18 have declined over 50%
following HPV vaccine introduction among girls ages 14–19 in the
U.S., yet national immunization rates are far below the Healthy Peo-
ple 2020 goal of 80% completion among adolescent females (Healthy
People, 2020 Topics & Objectives: U.S. Department of Health and
Human Services, 2014; Accelerating HPV Vaccine Uptake: Urgency
for Action to Prevent Cancer. A Report to the President of the
United States from the President's Cancer Panel. Bethesda MD: Na-
tional Cancer Institute, 2014). To our knowledge, this is the ﬁrst
study to examine factors related to HPV vaccine completion using
the 2012 NIS-Teen survey.
The ACIP has recommended that females ages 11–12 are to re-
ceive three doses of the HPV vaccine since 2006 (Centers for
Disease Control and Prevention (CDC). MMWR 2007). These results
indicate that adolescent females are not receiving the HPV vaccine
at recommended ages. Despite parental concerns about vaccine safe-
ty and efﬁcacy, (Markowitz et al., 2007; Oldach and Katz, 2012) clin-
ical trial data and safety monitoring by the CDC, FDA and vaccine
manufacturers indicate that the vaccine is highly safe and risk for se-
rious reaction to the HPV vaccine is extremely rare (Centers for
Disease Control and Prevention. National, Regional, State, and
Selected Local Area Vaccination Coverage Among Adolescents Aged
13–17 Years — United States, 2013; Kepka et al., 2014; Gee et al.,
2011; Chao et al., 2012; Klein et al., 2012). HPV vaccine administra-
tion is optimal during this age, when adolescents have the best
immune response to the vaccination (Accelerating HPV Vaccine
Uptake: Urgency for Action to Prevent Cancer. A Report to the
President of the United States from the President's Cancer Panel.).
Providers and parents need to recognize the full-panel of recom-
mended adolescent vaccinations and improve primary care by
adhering to recommended vaccine schedules.
Future studies are needed to investigate the importance of pairing
HPV vaccination with other recommended adolescent immunizations,
encouraging providers tomake strong recommendations for the receipt
of HPV vaccination, and clinic-based parent and patient reminder sys-
tems for 3-dose series completion.
Limitations
This study is limited by non-response among the NIS-Teen sample,
with adequate provider-veriﬁed vaccination data available among
only 56.4% of cellular and 62% of landline respondents. After weighting
adjustments, bias may persist (National State Vaccination Coverage
Among Adolescents Aged 13–17 Years — United States, 2012, 2014).
Lastly, only one multivariable regression model was included in our
analyses.
Conclusions
Future development of multifaceted, comprehensive strategies
to improve clinical recommendation and administration of theHPV vac-
cine series is needed, including: strong and consistent provider
recommendations, use of electronic health records and informationsystems to incorporate reminder systems for adolescents who are due
for HPV vaccination, and policies that ensure adequate provider reim-
bursement for administration of the HPV vaccine series (Accelerating
HPV Vaccine Uptake: Urgency for Action to Prevent Cancer. A Report
to the President of the United States from the President's Cancer
Panel). Moreover, community outreach and education promoting HPV
vaccination as a cancer preventionmethod, and addressing adolescents'
and caregivers' concerns about vaccine safety and efﬁcacy, may also im-
prove the uptake of the HPV vaccine.
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